The Effects of a Monoclonal Antibody Directed against Tumor Necrosis Factor-α in Asthma

Abstract

Treatment with infliximab was well tolerated and caused a decrease in the number of patients with exacerbations in symptomatic moderate asthma. The promising preliminary findings underscore the need to evaluate therapy directed against TNF-alpha in larger trials enrolling patients with more severe asthma.